GlassScriptPhysician profile
Yacharter Yang
NPI 1548327190
$7,374.75
in general payments reported to CMS, 2019-2025
17 companies · $3,592 in 2025
The $3,592 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $612 · 2023: $1,106 · 2024: $1,912 · 2025: $3,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,541 · Consulting Fee: $740 · Education: $186 · Travel and Lodging: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,540.98 |
| Consulting Fee | $740.00 |
| Education | $186.49 |
| Travel and Lodging | $142.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,483.46 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $1,137.78 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $695.81 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $695.54 | 2022-2025 | Caplyta |
| Alkermes, INC. | $693.14 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $662.16 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $653.90 | 2021-2025 | Ingrezza |
| Abbvie INC. | $355.20 | 2023-2025 | |
| Lilly USA, LLC | $337.69 | 2023-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $234.90 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Intra-Sana Laboratories | $119.48 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Luye Pharma (USA) LTD. | $87.24 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $83.06 | 2024-2025 | Trintellix |
| Indivior INC. | $70.04 | 2021-2024 | Perseris |
| Merck Sharp & Dohme LLC | $22.08 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $21.66 | 2024 | Tlando |
| Pfizer INC. | $21.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yacharter Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.